Cancer stem cell immunophenotypes in oral squamous cell carcinoma

Autor(es)

Oliveira, Lucinei R. ^[1] ; Oliveira-Costa, Joao P. ^[2] ; Araujo, Iana M. ^[3] ; Soave, Danilo F. ^[4] ; Zanetti, Juliana S. ^[5] ; Soares, Fernando A. ^[6] ; Zucoloto, Sergio ^[7] ; Ribeiro-Silva, Alfredo ^[8]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo. Ribeirao Preto Med Sch

^[2] Univ Sao Paulo. Ribeirao Preto Med Sch

^[3] Univ Sao Paulo. Ribeirao Preto Med Sch

^[4] Univ Sao Paulo. Ribeirao Preto Med Sch

^[5] Univ Sao Paulo. Ribeirao Preto Med Sch

^[6] AC Camargo Canc Hosp. Dept Pathol Anat

^[7] Univ Sao Paulo. Ribeirao Preto Med Sch

^[8] Univ Sao Paulo. Ribeirao Preto Med Sch

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF ORAL PATHOLOGY & MEDICINE; v. 40, n. 2, p. 135-142, FEB 2011.
• Citações Web of Science: 22

Resumo

Background: The presence of cancer stem cell (CSC) antigens can be evidenced in some human tumors by phenotypic analysis through immunostaining. This study aims to identify a putative CSC immunophenotype in oral squamous cell carcinoma (OSCC) and determine its influence on prognosis. Methods: The following data were retrieved from 157 patents: age, gender, primary anatomic site, smoking and alcohol intake, recurrence, metastases, histologic classification, treatment, disease-free survival (DFS), and overall survival (OS). An immunohistochemical study for CD44 and CD24 was performed in a tissue microarray of 157 paraffin blocks of OSCCs. Results: In univariate analysis, the immunostaining pattern showed significant influences in relation to OS for alcohol intake and treatment, as well as for the CD44+ and CD44-/CD24- immunophenotypes. The multivariate test confirmed these associations. Conclusions: Based on our results, the CD44 immunostaining and the absence of immunoexpression of these two investigated markers can be used in combination with other clinicopathologic information to improve the assessment of prognosis in OSCC. (AU)

• Processo FAPESP: 08/06461-1 - O papel da hipóxia tumoral na fisiopatogênese dos carcinomas mamários de imunofenótipo CD44+CD24-
• Beneficiário: Alfredo Ribeiro da Silva
• Modalidade de apoio: Auxílio à Pesquisa - Regular